NCT05505162 - Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 24, 2022

Primary Completion Date

January 10, 2023

Study Completion Date

January 10, 2023

Conditions

Healthy Female Participants

Interventions

DRUG

Zibotentan

Participants will receive two capsules of Zibotentan orally QD from day 6-19.

DRUG

EE/LNG

Participants will receive two tablets of EE and LNG once on Day 1 and Day 15 as a combined oral dose.

Trial Locations (1)

Research Site, Brooklyn